Document Detail

Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis.
MedLine Citation:
PMID:  9650946     Owner:  NLM     Status:  MEDLINE    
Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) is an emerging problem of great importance to public health, with higher mortality rates than drug-sensitive TB, particularly in immunocompromised patients. MDR-TB patients require treatment with more-toxic second-line drugs and remain infectious for longer than patients infected with drug-sensitive strains, incurring higher costs due to prolonged hospitalization. It is estimated that 90% of United Kingdom rifampin-resistant isolates are also resistant to isoniazid, making rifampin resistance a useful surrogate marker for multidrug resistance and indicating that second- and third-line drugs to which these isolates are susceptible are urgently required. Resistance in approximately 95% of rifampin-resistant isolates is due to mutations in a 69-bp region of the rpoB gene, making this a good target for molecular genotypic diagnostic methods. Two molecular assays, INNO-LiPA Rif.TB (Innogenetics, Zwijndrecht, Belgium) and MisMatch Detect II (Ambion, Austin, Tex.), were performed on primary specimens and cultures to predict rifampin resistance, and these methods were compared with the resistance ratio method. A third method, the phenotypic PhaB assay, was also evaluated in comparison to cultures in parallel with the genotypic assays. In an initial evaluation 16 of 16, 15 of 16, and 16 of 16 rifampin-resistant cultures (100, 93.8, and 100%, respectively), were correctly identified by line probe assay (LiPA), mismatch assay, and PhaB assay, respectively. Subsequently 38 sputa and bronchealveolar lavage specimens and 21 isolates were received from clinicians for molecular analysis. For the 38 primary specimens the LiPA and mismatch assay correlated with culture and subsequent identification and susceptibility tests in 36 and 38 specimens (94.7 and 100%), respectively. For the 21 isolates submitted by clinicians, both assays correlated 100% with routine testing.
S A Watterson; S M Wilson; M D Yates; F A Drobniewski
Related Documents :
18069086 - The antimicrobial activity of copper and copper alloys against nosocomial pathogens and...
402706 - Mycobacterium tuberculosis resistance to rifampicin and ethambutol: a clinical survey.
10074516 - Molecular evidence for heterogeneity of the multiple-drug-resistant mycobacterium tuber...
23605346 - Mycotoxin production in a carbendazim-resistant strain of fusarium sporotrichioides.
21599296 - Alignment statistics of active and passive scalar gradients in turbulent stratified fla...
7390536 - Analysis of growth dynamics and the relationship to the fluctuations in alkaline phosph...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical microbiology     Volume:  36     ISSN:  0095-1137     ISO Abbreviation:  J. Clin. Microbiol.     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-09-28     Completed Date:  1998-09-28     Revised Date:  2013-04-18    
Medline Journal Info:
Nlm Unique ID:  7505564     Medline TA:  J Clin Microbiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1969-73     Citation Subset:  IM    
Public Health Laboratory Service Mycobacterium Reference Unit, Department of Microbiology, King's College School of Medicine and Dentistry, King's College Hospital (Dulwich), London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antitubercular / pharmacology*
Bacterial Typing Techniques
Base Sequence
Bronchoalveolar Lavage Fluid / microbiology
DNA, Bacterial / analysis
Drug Resistance, Microbial / genetics
Drug Resistance, Multiple / genetics
Molecular Sequence Data
Mycobacteriophages / physiology
Mycobacterium tuberculosis / drug effects*,  isolation & purification,  virology
Nucleic Acid Hybridization
Polymerase Chain Reaction / methods
RNA, Bacterial / analysis
Reagent Kits, Diagnostic
Rifampin / pharmacology*
Sequence Analysis, DNA
Sputum / microbiology
Tuberculosis, Multidrug-Resistant / diagnosis,  microbiology*
Tuberculosis, Pulmonary / diagnosis,  microbiology*
Grant Support
//Wellcome Trust
Reg. No./Substance:
0/Antibiotics, Antitubercular; 0/DNA, Bacterial; 0/RNA, Bacterial; 0/Reagent Kits, Diagnostic; 13292-46-1/Rifampin; EC 3.1.-/Ribonucleases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in s...
Next Document:  Evaluation of intestinal protozoan morphology in human fecal specimens preserved in EcoFix: comparis...